Global Onychomycosis (Tinea Unguium) Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Onychomycosis (Tinea Unguium) Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate.
Onychomycosis (Tinea Unguium) Drug is the drug for the treatment of the disease.
Onychomycosis (Tinea Unguium) Drug report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Onychomycosis (Tinea Unguium) Drug market is projected to reach US$ 4901.7 million in 2034, increasing from US$ 3288 million in 2022, with the CAGR of 5.8% during the period of 2024 to 2034. Demand from Age under 18 and Age 18-50 are the major drivers for the industry.
Global Onychomycosis (Tinea Unguium) Drug key players include Pfizer, J&J, Novartis, Galderma pharm, Valeant Pharma, etc. Global top five manufacturers hold a share about 35%.
North America is the largest market, with a share about 30%, followed by Europe and China both have a share over 45 percent.
In terms of product, Oral Medication is the largest segment, with a share over 70%. And in terms of application, the largest application is Age above 50, followed by Age under 18.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Onychomycosis (Tinea Unguium) Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Pfizer
Yangtze River
Torrent Pharma
J&J
Chengdu Brilliant
Novartis
Qilu Pharmaceutical
Xiuzheng Pharmaceutical
Hubei Hengan
TARO
Perrigo
Galderma pharm
Zhejiang Deyer
Valeant Pharma
Moberg
Segment by Type
Oral Medication
External Medicine
Age under 18
Age 18-50
Age above 50
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Onychomycosis (Tinea Unguium) Drug market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Onychomycosis (Tinea Unguium) Drug introduction, etc. Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Onychomycosis (Tinea Unguium) Drug market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Onychomycosis (Tinea Unguium) Drug is the drug for the treatment of the disease.
Onychomycosis (Tinea Unguium) Drug report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Onychomycosis (Tinea Unguium) Drug market is projected to reach US$ 4901.7 million in 2034, increasing from US$ 3288 million in 2022, with the CAGR of 5.8% during the period of 2024 to 2034. Demand from Age under 18 and Age 18-50 are the major drivers for the industry.
Global Onychomycosis (Tinea Unguium) Drug key players include Pfizer, J&J, Novartis, Galderma pharm, Valeant Pharma, etc. Global top five manufacturers hold a share about 35%.
North America is the largest market, with a share about 30%, followed by Europe and China both have a share over 45 percent.
In terms of product, Oral Medication is the largest segment, with a share over 70%. And in terms of application, the largest application is Age above 50, followed by Age under 18.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Onychomycosis (Tinea Unguium) Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Pfizer
Yangtze River
Torrent Pharma
J&J
Chengdu Brilliant
Novartis
Qilu Pharmaceutical
Xiuzheng Pharmaceutical
Hubei Hengan
TARO
Perrigo
Galderma pharm
Zhejiang Deyer
Valeant Pharma
Moberg
Segment by Type
Oral Medication
External Medicine
Segment by Application
Age under 18
Age 18-50
Age above 50
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Onychomycosis (Tinea Unguium) Drug market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Onychomycosis (Tinea Unguium) Drug introduction, etc. Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Onychomycosis (Tinea Unguium) Drug market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices